Standardization of Myocardial Protection: Comment on Cardiac Surgery 2023 Reviewed

Abstract

There have been few recent innovations since the introduction of cardioplegia more than 50 years ago. Surprisingly, cardioplegia as one of the most essential steps in terms of heart muscle protection during a surgical procedure requiring cardiac arrest has never been really standardized. As a consequence, a considerable variety of cardioplegic solutions and applications have developed: cold versus warm, crystalloid versus blood cardioplegia, antegrade versus retrograde or both, as well as different time schedules for repeated administration. A new cardioplegia solution, called Cardioplexol™, has recently received CE marking approval as a drug following two phase III studies. Cardioplexol™ shows several advantages: the administration follows a very simple protocol, minimizing the risk of errors in manipulation, and diastolic arrest occurs immediately, thus allowing immediate start of the cardiac work once the aorta has been cross clamped. The very low volume of crystalloid solution (e.g., 100 mL as induction and a second application of 100 mL following 45–60 minutes of ischemia) avoids hemodilution and therefore the need for filtration during surgery. In addition, the injection through the aortic root canula eliminates the need for an additional cardioplegia pump and its disposable tubing system. This simplified cardioplegia that is not inferior to Buckberg solution has the potential for standardization of myocardial protection protocols.

Keywords

myocardial protection/cardioplegia (incl. metabolism) - cardiopulmonary bypass - CPB - coronary artery bypass grafts surgery - CABG - heart valve surgery - ischemia/reperfusion

Publication History

Received: 09 October 2024

Accepted: 29 November 2024

Accepted Manuscript online:
09 December 2024

Article published online:
28 January 2025

• References

• 1 Kirov H, Caldonazo T, Mukharyamov M. et al. Cardiac Surgery 2023 reviewed. Thorac Cardiovasc Surg 2024; 72 (05) 346-357
• 2 Mukharyamov M, Schneider U, Kirov H, Caldonazo T, Doenst T. Myocardial protection in cardiac surgery—hindsight from the 2020s. Eur J Cardiothorac Surg 2023; 64 (06) 64
• 3 Tevaearai HT, Weiss G, Landowski P. et al. Single-centre, single blind, randomized, active-controlled phase 3 non-inferiority study to investigate the safety and efficacy of the cardioplegic solution Cardioplexol™. Front Cardiovasc Med 2024
• 4 Tevaearai HT, Viena NT, Winkler A. et al. A multi-center, open label, single group, observational clinical trial to investigate the effects of training on the administration of Cardioplexol™. Front Cardiovasc Med 2024
• 5 Hemmerich C, Heep M, Gärtner U, Taghiyev ZT, Schneider M, Böning A. Myocardial recovery, metabolism and structure after cardiac arrest with cardioplexol. Thorac Cardiovasc Surg 2023; epub ahead of print
• 6 Carrel T. Reduced invasiveness of cardiopulmonary bypass: the mini-circuit and the micro-cardioplegia. J Cardiovasc Dev Dis 2023; 10 (07) 290
• 7 Tevaeara Stahel H, Barandun S, Kaufmann E. et al. Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures. J Thorac Dis 2019; 11 (Suppl. 10) S1471-S1479
• 8 Gygax E, Kaeser HU, Stalder M. et al. Type II minimal-invasive extracorporeal circuit for aortic valve replacement: a randomized controlled trial. Artif Organs 2018; 42 (06) 620-629
• 9 Kadner A, Heinisch PP, Bartkevics M. et al. Initial experiences with a centrifugal-pump based minimal invasive extracorporeal circulation system in pediatric congenital cardiac surgery. J Thorac Dis 2019; 11 (Suppl. 10) S1446-S1452
• 10 Carrel T. Sinus of Valsalva aneurysm: different modes of presentation and techniques of repair. J Cardiovasc Dev Dis 2024; 11 (04) 100